Drug, bio-affecting and body treating compositions inventions

20100021378 - Imaging protocols: P

20100021379 - Chemical antibodies for immunotherapy and imaging: The present invention provides antibody conjugates comprising a targeting agent covalently attached to an antibody or fragment thereof. The antibody conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, infectious diseases,... Agent: Townsend And Townsend And Crew, LLP

20100021380 - Dieghylenetriaminepentaacetic acid (dtpa)-modified ferrofluid, preparation method of the same and uses of the same in preparation of peptide ferrofluid: A present invention relate to a diethylenetriaminepentaacetic acid (DTPA)-modified ferrofluid and a preparation method of the same. The DTPA-ferrofluid contains DTPA and a nano ferrofluid. The DTPA-ferrofluid can be further mixed with a peptide. Unmodified or modified peptide ferrofluids prepared from the DTPA-modified ferrofluid, such as unmodified or modified octreotide-containing... Agent: Wpat, PC Intellectual Property Attorneys

20100021381 - Natriuretic peptide-mediated imaging of atherosclerotic plaque: Tracers comprising an oligopeptide comprising a fragment of a natriuretic peptide, wherein the fragment comprises the sequence Arg-Ile-Asp-Arg-Ile (SEQ ID NO.: 1), and a signaling moiety, are disclosed. Further disclosed are methods of imaging atherosclerotic plaque by PET scanning or MRI using a tracer.... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20100021385 - Benzoxazole derivatives: It is intended to provide a benzoxazole derivative or a pharmaceutically acceptable salt or solvate thereof which is useful in the early diagnosis of a conformation disease; a composition or a kit containing the same for diagnosing a conformation disease; a medical composition for treating and/or preventing a conformation disease;... Agent: Nixon Peabody, LLP

20100021383 - Molecular probe for sphingolipids: There is presently provided a probe comprising an isolated sphingolipid binding domain (SBD) polypeptide, wherein the isolated SBD polypeptide is capable of binding to a sphingolipid, and methods and uses relating to such a probe.... Agent: Klarquist Sparkman, LLP

20100021382 - Pyrazine derivatives and uses thereof: Disclosed herein are pyrazine derivatives and methods of using the same.... Agent: Mallinckrodt Inc.

20100021384 - Use of vhh antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100021387 - Methods for inducing reversible stasis: The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as... Agent: Woodcock Washburn LLP

20100021386 - Treatment, prevention,and reversal of alcohol-induced liver disease: This invention relates to methods for treating, preventing, or reversing liver disease or damage produced by chronic alcohol intake by administering at least one peroxisome proliferator activated receptor (PPAR) agonist.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100021388 - Benzothiazole derivative compounds, compositions and uses: This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s).... Agent: Foley And Lardner LLP Suite 500

20100021391 - Novel nanoparticles for biofilm targeting: The present invention is directed to novel compositions and methods utilizing nanoparticles comprising protein cages for delivery of imaging and antimicrobial agents to biofilm forming bacterial colonies.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100021389 - Radiographic contrast agent for postmortem, experimental and diagnostic angiography: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast... Agent: Sughrue Mion, PLLC

20100021390 - Fluorescent analogs of the islet amyloid polypeptide: The present invention relates to methods and compositions for the investigation of amyloid formation. In preferred embodiments, amyloid formation associated with type II diabetes is monitored by fluorescence spectroscopic measurements of the activity of p-cyano-phenylalanine-substituted islet amyloid polypeptide, and derivatives thereof, under an amyloid-forming condition. In some embodiments, the amyloid-forming... Agent: Peter G. Carroll Medlen & Carroll, LLP

20100021392 - Vapor-phase application of spinosyn for the control of pest, and formulations and products utilizing the same: The present invention relates to the vapor-phase application of at least one spinosyn to treat pests including, for example, adult mosquitoes and houseflies.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100021393 - Pharmaceutical compositions comprising effervescent agents and fenofibrate: A pharmaceutical composition comprising at least one effervescent agent and a fibrate and a process for making such composition. The fibrate is fenofibrate and the effervescent agent are in a dosage form. The dosage form increases dissolution and absorption of fenofibrate in biological conditions where the form contacts acidic gastric... Agent: Paul D. Yasger Abbott Laboratories

20100021395 - Crystalline forms of a biphenyl compound: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and... Agent: Theravance, Inc.

20100021394 - High penetration prodrug compositions of 1h-imidazo[4,5-c]quinolin-4-amines and 1h-imidazo[4,5-c]quinolin-4-amine-related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier... Agent: Perkins Coie LLP

20100021396 - Tinting mousse: Aerosol-foam products or pump-foam products for simultaneous coloring or tinting and temporary deformation of keratinic fibers, encompassing a foam-type or foamable composition that contains at least one film-forming and/or setting polymer and at least one anionic direct dye.... Agent: Connolly Bove Lodge & Hutz LLP

20100021397 - Droplet cleaning fluid used for cleaning teeth which includes a polymer additive: The fluid for use in a liquid droplet-based oral care system for teeth includes a water-soluble, human-consumable polymer additive of selected concentration and molecular weight which maintains the size of the resulting droplets to a desired range of 25-30 microns, at a flow rate within the range of 10-20 milliliters... Agent: Philips Intellectual Property & Standards

20100021400 - Active sunscreen composition: The invention relates to topical compositions comprising a fluorescent dye that absorbs UVA and UVB radiation and converts it into a healing light, in combination with a dermatologically acceptable excipient. The compositions of the invention are useful for repairing photo-damaged skin cells and reducing or preventing future skin damage as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100021398 - Compositions and methods for lightening skin and protecting skin from ultraviolet radiation with glutathione: A glutathione composition for lightening or protecting skin is disclosed together with a method for lightening skin or protecting the skin from the effects of ultraviolet radiation is accomplished by administering glutathione to the skin. The glutathione may be glutathione modified with at least one fatty acid or the glutathione... Agent: Greenberg Traurig LLP (la)

20100021402 - Compounds, formulations, and methods for ameliorating telangiectasis: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at... Agent: Hoffmann & Baron, LLP

20100021404 - Cosmetic composition with skin tightening effect: t

20100021399 - Cosmetic or dermatological preparations comprising n-acetylcysteine: The present invention relates to odour improved dermatological or cosmetic preparations comprising N-acetylcysteine and a polyol system containing one or more polyols as masking odour agents. The emulsions of the present invention are useful in the treatment of dermatological disorders or cosmetic skin conditions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100021403 - Dispersions of inorganic particulates containing alkoxycrylene: e

20100021401 - Method for treating skin: The method is for treating skin. A peptide is selected that affects a receptor so that the receptor is receptive to the peptide. The selected peptide is dissolved in a solution to form a peptide solution. The skin is vibrated to generate heat without reducing the peptide in the peptide... Agent: Fasth Law Offices (rolf Fasth)

20100021405 - External preparation for skin: The present invention provides an external preparation for skin comprising a phospholipid having an iodine value of 80 to 110, ethanol in an amount of 55 to 83 wt % and water in an amount of 15 to 43 wt %, which is improved in it's preparation stability by suppressing... Agent: Birch Stewart Kolasch & Birch

20100021408 - Block polymer, cosmetic composition comprising it and cosmetic treatment process: e

20100021409 - Film forming personal care compositions: A shaving composition, comprising a base composition, comprising a film forming system comprising one or more film forming materials; and one or more water soluble or water dispersible surface active agents; and at least one suspended benefit agent disposed within the base composition.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100021410 - Novel hair treatment compositions: An aqueous and/or aqueous alcoholic leave-in composition to reduce the time to dry wet hair containing (a) at least one wetting agent having a Draves wetting value of 100 seconds of less selected in an amount sufficient to enhance the hydrophobicity of hair thereby causing water to dewet the hair,... Agent: Avon Products, Inc.

20100021406 - Process for making up keratin fibres and packaging assembly: The present invention relates to a cosmetic process for making up or for the non-therapeutic care of keratin fibres, comprising the application to the keratin fibres of a cosmetic composition containing at least one compound or a mixture of compounds, which, when the composition is brought to a temperature of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100021407 - Hair care formulations comprising uv absorbers and certain silicone derivatives: This invention relates to hair conditioning formulations comprising at least one aminofunctional polyorganosiloxane. Furthermore, the invention relates to the use of these formulations for the treatment of keratin-containing fibers, preferably human hair.... Agent: Joann Villamizar Ciba Specialty Chemical Corporation

20100021411 - Cosmetic depilatory composition: A cosmetic cold-wax depilatory composition is provided The depilatory composition comprises a hydrocarbon resin, from 50% to 99% by weight and a flexibilizer or plasticizer, from 0 5% to 10% by weight Methods of applying the composition to a strip of material for removal of hair without the need for... Agent: Church & Dwight Co., Inc.

20100021412 - Reduction of hair growth: Mammalian hair growth is reduced by applying an agonist of farnesoid X receptor.... Agent: Fish & Richardson P.C.

20100021413 - Malodor counteracting compositions: m

20100021414 - Bioabsorbable adhesive compounds and compositions: Bioabsorbable compounds which include a polyalkylene oxide backbone with two or more isocyanate substituents are useful as one component adhesives. Absorbable compositions useful as a two component adhesive contain a) a polyethylene oxide having two or more amine substituents with b) a bioabsorbable diisocyanate compound, or alternatively contain a) a... Agent: Tyco Healthcare Group Lp

20100021415 - Cosmetic use of organic resinates: A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a... Agent: Young & Thompson

20100021416 - Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100021417 - Acetate-containing mating disruptant and mating disruption method using the same: Provided are a mating disruptant having an improved mating disruption effect against pest insects. Specifically, provided is a mating disruptant for the control of pest insects whose natural sex pheromone composition is substantially free of an alcohol and comprises one or more acetates, the disruptant comprising the one or more... Agent: Beem Patent Law Firm

20100021418 - Weather resistant granular slug, snail and insect bait: The present disclosure is directed to a physical and chemical formulation designed to be attractive to, and eaten by, terrestrial mollusks, specifically slugs and snails. Optionally, the formulation is also attractive to and toxic to insects. Upon being eaten and after a set delay, the invention is designed to kill... Agent: Luedeka, Neely & Graham, P.C.

20100021419 - Stable pharmaceutical composition comprising granulocyte-colony stimulating factor: The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF).... Agent: Lek (slovenia) - Luedeka, Neely & Graham, P.C.

20100021420 - Combinations of pyrazole derivatives for the inhibition of cdks and gsk's: A combination comprising (a) a compound of formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O) or 0(C═O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by... Agent: Heslin Rothenberg Farley & Mesiti PC

20100021421 - Fusion proteins and methods for modulation of immune response: A fusion protein comprising GM-CSF and IL-15 is described. The fusion protein has unexpected immune suppressive properties and is useful in a variety of therapeutic applications.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100021423 - Heterocyclic antiviral compounds: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20100021422 - Methods and compositions for delivery of exogenous factors to nervous system sites: The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site... Agent: Darby & Darby P.C.

20100021425 - 1'-substituted carba-nucleoside analogs for antiviral treatment: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.... Agent: Gilead Sciences Inc

20100021424 - Method for identifying whether a patient will be responder or not to immunotherapy: The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100021426 - Methods for making and compositions comprising fermentation products of cordyceps sinensis: The present invention relates to novel and non-obvious methods and media for preparing fermentation products of Cordyceps sinensis. The present invention also relates to novel and non-obvious compositions comprising fermentation products of Cordyceps sinensis produced by the methods of the invention or obtained from other sources. The present invention also... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100021427 - Use of antiviral peptides for treatment of infections caused by drug-resistant hiv: The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.... Agent: Milstein Zhang & Wu LLC

20100021429 - Cladribine regimen for treating multiple sclerosis: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100021428 - Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel): The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.... Agent: Wolf Greenfield & Sacks, P.C.

20100021443 - Method of preparing lung alveolar epithelial type ii cells derived from embryonic stem cells: A method of preparing a population of in vitro cultured cells of alveolar epithelial type II (ATII) cell lineage derived from at least one embryonic stem cell is disclosed which comprises (a) culturing said at least one embryonic stem cell in vitro in a medium comprising Matrigel®, to produce differentiated... Agent: Conley Rose, P.C. David A. Rose

20100021430 - Horse feed and treatment methods: A horse feed mixture and method of treating a horse is disclosed. Feed mixtures disclosed contains more than 15% spelt, vegetable oil and vitamins and have less than 20% by weight fillers and less than 5% by weight sugar. The feed may be used to treat ailments including underweight condition,... Agent: Andrew C. Aitken

20100021445 - Agent for reducing visceral fat: Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of... Agent: Knobbe Martens Olson & Bear LLP

20100021444 - Blood-adiponectin-concentration increase-accelerator and/or decrease-inhibitor thereof and visceral fat accumulation inhibitor: Disclosed is an agent for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, or a food, beverage or animal feed for accelerating the increase in and/or preventing the decrease in the blood adiponectin level, which comprises a culture or cell of a lactic acid bacterium... Agent: Greenblum & Bernstein, P.L.C

20100021446 - Use of polypeptides against diseases caused by protozoans: The present invention relates to the use of isolated polypeptides as coccidiostat and/or histomonastat. An example of a polypeptide of the invention is the so-called L12 protein from Bacillus licheniformis ATCC 14580.... Agent: Novozymes North America, Inc.

20100021431 - Agent for promoting the production of thioredoxin: A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a... Agent: Oliff & Berridge, PLC

20100021432 - Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is... Agent: Fish & Richardson P.C.

20100021433 - Disease treatment via developing non-syngeneic graft transplantation: A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100021434 - Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases: Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100021438 - Kidney derived stem cells and methods for their isolation, differentiation and use: The invention relates generally to methods for isolation and culture of kidney stem cells, cells isolated by the methods, and therapeutic uses for those cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100021442 - Method for promoting immunotherapy using an agent for elevating dendritic cell precursor level in blood: Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a... Agent: Birch Stewart Kolasch & Birch

20100021439 - Methods and compositions for treating intervertebral disc degeneration: A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans... Agent: Howrey LLP-hn

20100021441 - Mhc molecule-binding tumor-associated peptides: The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100021436 - Multipotent adult stem cell derived from canine umbilical cord blood, placenta and canine fetus heart, method for preparing the same and cellular therapeutics containing the same: The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated... Agent: Moore & Van Allen PLLC

20100021437 - Neural stem cells derived from induced pluripotent stem cells: The present invention provides novel populations of neural stem cells derived from induced pluripotent stem cells, and methods for making and using the same.... Agent: Foley & Lardner LLP

20100021435 - Pancreatic islet-like cells: The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MD-SCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided.... Agent: Polsinelli Shughart PC

20100021440 - Use of tropoelastin for repair or restoration of tissue: The present invention relates to tropoelastin and to tissue repair and restoration using elastic materials. Disclosed is a process for producing an elastic material from tropoelastin including heating a solution of tropoelastin having an alkaline pH to form an elastic material from the tropoelastin in the solution. Also disclosed are... Agent: Bozicevic, Field & Francis LLP

20100021447 - Medicament for treating problems relating to fertility and pregnancy, and autoimmune diseases, and for inducing an immunological tolerance in transplant patients, and method for producing said medicament: A medicament for treating pregnancy disorders or for inducing an immunological tolerance in patients with autoimmune diseases or transplantation processes, contains at least one each of a) a precursor hCG β subunit of the human choriongonadotropine (hCG) selected from hCG β6 according to SEQ ID NO 1 or SEQ ID... Agent: Gudrun E. Huckett Draudt

20100021449 - Angiogenin complexes (angex) and uses thereof: Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20100021448 - I-crei meganuclease variants with modified specificity, method of preparation and uses thereof: Method of preparing 1-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100021450 - Lys k endolysin is synergistic with lysostaphin against mrsa: Multi-drug resistant superbugs are a persistent problem in modern health care. LysK is a staphylococcal bacteriophage endolysin from the phage K. It is a peptidoglycan hydrolase enzyme that can lyse many staphylococcal strains and thus is a potent antimicrobial against S. aureus, including MRSA. Lysostaphin is a bacteriocin secreted by... Agent: Usda, Ars, Ott

20100021454 - Antibodies with immune effector activity and that internalize in endosialin-positive cells: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic... Agent: Woodcock Washburn LLP

20100021452 - Compositions and methods of use for therapeutic antibodies: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated... Agent: Novartis Institutes For Biomedical Research, Inc.

20100021453 - Targeting of triacylclycerol synthase gene for tuberculosis treatment: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.... Agent: Timothy H. Van Dyke Beusse Wolter Sanks Mora & Maire, P.A.

20100021451 - Uses and compositions for treatment of ankylosing spondylitis: The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a... Agent: Mccarter & English, LLP Boston

20100021457 - Detection system and uses therefor: A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group;... Agent: Marshall, Gerstein & Borun LLP

20100021456 - Drug for inhibiting,preventing or treatment of rheumatoid arthritis: s

20100021461 - Immunoglobulin formulation and method of preparation thereof: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of... Agent: Crowell & Moring LLP Intellectual Property Group

20100021455 - Methods for diagnosis and treatment of crohn's disease: The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1... Agent: Davis Wright Tremaine LLP/los Angeles

20100021460 - Methods of treating autoimmune diseases using cd4 antibodies: Methods of treating autoimmune disorders in mammalian subjects using non-depleting CD4 antibodies, alone or in combination with other compounds, are provided.... Agent: Genentech, Inc.

20100021458 - Polycyclic agents for the treatment of respiratory syncytial virus infections: The present invention relates to polycyclic antiviral compounds, and salts thereof, methods for their preparation and compositions containing them, and the use of the compounds and composition in the treatment of viral infections.... Agent: Jones Day

20100021459 - Polypeptide constructs for intracellular delivery: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method... Agent: Wolf Greenfield & Sacks, P.C.

20100021462 - Gasp1: a follistatin domain containing protein: The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level... Agent: Wyeth LLC/finnegan Henderson, LLP

20100021466 - Antagonistic human light-specific human monoclonal antibodies: Provided herein are antibodies, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as... Agent: Jones Day

20100021463 - Antibodies to ip-10 for treating bone diseases with bone destruction: The present invention is directed to providing the IP-10 protein (interferon-γ-inducible protein 10) as a novel therapeutic target relating to the etiology of bone diseases with bone destruction associated with RNAKL expression and osteoclast formation. More specifically, the present invention relates to (i) a pharmaceutical composition for preventing or treating... Agent: Clark & Elbing LLP

20100021465 - Boris isoforms and methods of detecting and treating disease: A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a... Agent: Leydig, Voit & Mayer, Ltd.

20100021469 - Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present... Agent: Klarquist Sparkman, LLP

20100021467 - Method of detecting a cancer cell by aberrant expression of a human k+ ion channel: The present invention relates to a novel human K+ ion channel, to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to antibodies specifically directed to the novel K+ ion channel and to pharmaceutical compositions and diagnostic kits containing at least... Agent: Ropes & Gray LLP

20100021464 - Methods of wound care and treatment: Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface... Agent: Davis Wright Tremaine, LLP/seattle

20100021468 - Novel mhc class ii restricted t cell epitopes from the cancer anitgen, ny eso-1: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products... Agent: Leydig, Voit & Mayer, Ltd.

20100021471 - Carbon nanotube-based drug delivery systems and methods of making same: e

20100021470 - Monoclonal antibody production by ebv transformation of b cells: A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an... Agent: Global Patent Group - Hmb

20100021472 - Methods for diagnosing and treating cancer: Aspects of the present invention relate to molecular biology and medicine. More specifically, some embodiments include methods for treating and/or diagnosing inflammation and/or cancer using agents that inhibit the binding of a pro-inflammatory protein or protein complex (e.g., S100A8 and/or S100A9) to a carboxylated glycan expressed on a myeloid (e.g.,... Agent: Knobbe Martens Olson & Bear LLP

20100021473 - Bispecific ligands with binding specificity to cell surface targets and methods of use therefor: Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100021476 - High affinity human antibodies to human il-4 receptor: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.... Agent: Regeneron Pharmaceuticals, Inc

20100021475 - Methods and compositions for inhibiting the growth of hematopoietic malignant cells: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100021474 - Methods and compositions for targeting hepsin: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.

20100021477 - Design and generation of human de novo pix phage display libraries: Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific... Agent: Philip S. Johnson Johnson & Johnson

20100021478 - Diagnostic antibody assay: The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.... Agent: Sonnenschein Nath & Rosenthal LLP

20100021479 - Monoclonal antibodies against cd30 lacking in fucosyl residues: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100021480 - Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same: This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is... Agent: LexyoumeIPGroup, LLC

20100021481 - Conjugates of an anti-tnf-alpha antibody: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.... Agent: Nektar Therapeutics

20100021482 - Novel death associated proteins, and thap1 and par4 pathways in apoptosis control: The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including... Agent: Knobbe Martens Olson & Bear LLP

20100021483 - Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugates: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing

20100021484 - Compositions, methods and kits relating to poxvirus subunit vaccines: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100021485 - Combination therapy method and formulation: This invention concerns a pharmaceutical formulation and method for treating autoimmune disorders. The formulation and method provide for a combination therapy regimen wherein two separate substances are administered to a patient having or predisposed to having the disorder. The two components comprise at least one immunomodulatory peptide and a chloroquine... Agent: Dla Piper LLP (us)

20100021488 - Hmgn polypeptides as immune enhancers and hmgn antagonists as immune suppressants: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition... Agent: Leydig, Voit & Mayer, Ltd.

20100021489 - Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100021486 - Tslp vaccine for the treatment of th2 mediated inflammatory conditions: The invention relates to compositions for the treatment of TH2 mediated inflammatory conditions. The compositions are vaccines comprising a non-primate TSLP or fragments thereof to be used as a vaccine to treat humans with excessive mediated inflammatory conditions. For the treatment of TH2 mediate inflammatory conditions in other non-human mammals... Agent: Bacon & Thomas, PLLC

20100021487 - Vaccines and methods for controlling adiposity: The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety.... Agent: Merchant & Gould PC

20100021490 - Preparation of soluble n-protein/truncated p-protein complexes or n-proteinssoluble in a virus of the paramyxoviridae family and use thereof in vaccines: The invention relates to a method for preparation of soluble N-protein/truncated P-protein complex of a virus of the family Paramyxoviridae, complexes prepared thus and the soluble N-proteins which may be isolated from said complexes. The invention further relates to vaccine compositions comprising said N-protein/truncated P-protein complexes or N-proteins from Paramyxoviridae.... Agent: Davidson, Davidson & Kappel, LLC

20100021491 - Protein kinase deficient, immunologically active cmvpp65 mutant cellular vaccines: This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100021492 - Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP 106-derived polypeptides. The... Agent: Foley And Lardner LLP Suite 500

20100021495 - Diet product comprising alginate: The present invention relates to a diet product comprising an alginate in an aqueous dissolved or swelled form at a pH value causing the alginate not to gel.... Agent: Sughrue Mion, PLLC

20100021493 - Extracts of aphanizomenon flos aquae and nutritional, cosmetic and pharmaceutical compositons containing the same: The invention provides extracts of the microalga Aphanizomenon Flos Aquae Aquae Ralfs ex Born. & Flah. Var. flos aquae (AFA Klamath) and biologically active components thereof, in particular AFA-phycocyanins, determined as the complex c-phycopcyanin/phycoerythrocyanin (including the chromophore phycoviolobilin), AFA-phytochrome and mycosporine-like aminoacids (MAAs), nutritional, cosmetic and pharmaceutical compositions containing the... Agent: Arent Fox LLP

20100021494 - Hepatitis-related preventive or therapeutic agents: The present disclosure relates to provide a novel hepatitis-related therapeutic or preventive agent. The present disclosure provides a hepatitis-related preventive or therapeutic agent including a phlorotannin.... Agent: Foley & Lardner LLP

20100021496 - Methods, kits, and antibodies for quantitative determination of parathyroid hormone molecules with intact c-terminus: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and C-terminal parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as chronic renal failure, hyperparathyroidism and related bone... Agent: Morrison & Foerster LLP

20100021497 - Ipv-dpt vaccine: The invention provides a process for producing a combined vaccine containing an inactivated Sabin strain of poliovirus, a Bordetella pertussis protective antigen, a diphtheria toxoid and a tetanus toxoid, the process including a step of producing a high-titer Sabin strain poliovirus. The inventive process for producing a combined vaccine, including... Agent: Foley And Lardner LLP Suite 500

20100021498 - Live, attenuated pneumococcal vaccine: This invention relates to a live mutated strain of S. pneumoniae which is incapable of expressing polysaccharide capsule, while still capable of colonizing the nasopharynx of the subject.... Agent: Pearl Cohen Zedek Latzer, LLP

20100021499 - Cell-based systems for producing influenza vaccines: The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can... Agent: Foley & Lardner LLP

20100021500 - Processes for treating subjects carrying viral infectious agent: This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination... Agent: Enzo Biochem, Inc.

20100021501 - Live vaccine strains of francisella: A strain of Francisella species wherein a gene which encodes for part of the glutamate metabolic pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as live prophylactic or therapeutic vaccine against infection by said Francisella species. Particularly effective strains... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100021502 - Compositions and methods of topical application and transdermal delivery of botulinum toxins stabililzed with polypeptide fragments derived from hiv-tat: This invention relates to novel compositions of botulinum toxin that are stabilized using HTV-TAT fragments or derivatives of HTV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments.... Agent: King & Spalding

20100021503 - Immunogenic composition: The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from S. aureus. Methods of using and processes to make an immunogenic composition are also described.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100021504 - Treatment and prevention of allergic airways diseases: The present invention provides a method for the treatment or prevention of an allergic airways disease in a subject, the method comprising administering to the subject a composition comprising Streptococcus pneumoniae or one or more antigens derived therefrom. Also provided are methods and compositions for inducing protective immunity against an... Agent: Merchant & Gould PC

20100021505 - Composition and method to prevent or reduce diarrhea and steatorrhea in hiv patients: Method of preventing or reducing diarrhea and/or steatorrhea in HIV-positive patients being treated with High Activity Antiretroviral drugs containing protease inhibitors, nucleoside reverse transcriptase inhibitors or non-nucleoside reverse transcriptase inhibitors. The method includes the steps of: administering to the HIV-positive patient a High Activity Antiretroviral drug containing a protease inhibitor,... Agent: The Law Office Of Imre Balogh

20100021507 - Method and composition for making an orally disintegrating dosage form: The present invention relates to a process for making orally disintegrating dosage forms and means for packaging such dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20100021506 - Nitric oxide gel apparatus and method: Gel strips containing reactants capable of reacting to form nitric oxide are maintained separate until application. Upon application, the gel strips are placed in contact with one another, and may mix, or operate by diffusion, to deliver nitric oxide directly to the stream of breathing air of a user. Adhesive... Agent: Pate Pierce & Baird

20100021509 - Cosmetics containing a multi-functional composite powder: This invention provides cosmetics containing a multi-functional composite powder having the properties of (a) an excellent adhesiveness, (b) an excellent extendability, (c) an appropriate glossy effect, (d) a homogeneous cosmetic film, (e) an appropriate covering capability, (f) a cosmetic film not causing a white masking, (g) a high compatibility between... Agent: Kanesaka Berner And Partners LLP

20100021511 - Dispersion composition, cosmetic preparation for skin care, and method for producing dispersion composition: The present invention provides: a dispersion composition including a carotenoid-containing oily component, the dispersion composition being obtained by mixing an aqueous dispersion containing emulsion particles containing the carotenoid-containing oily component and a phospholipid or a derivative thereof with an aqueous composition containing ascorbic acid or a derivative thereof and an... Agent: Solaris Intellectual Property Group, PLLC

20100021508 - Method for treating hypersensitive teeth: A method for imparting a teeth-desensitising effect to a food, cosmetic or pharmaceutical which comprises combining said food, cosmetic or pharmaceutical with a teeth-desensitising effective amount of a polyol.... Agent: Ostrolenk Faber Gerb & Soffen

20100021510 - Neuronal exocytosis inhibiting peptides: which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting... Agent: Foley And Lardner LLP Suite 500

20100021512 - Incontinence garments with a silver lining infection stopper: Antibiotics used to cure Uterine Tract Infections have resulted in the growth of MRSA. and other antibiotic resistant bacteria. The CDC guidelines state “Disposable diapers cause 95% of all UTI'S”. The procedures used for “prevention” are ineffective because millions of bacteria in incontinence garments continue to double every 20 minutes.... Agent: Stanley Arron

20100021513 - Absorbant substance and method of preparation thereof: The invention relates to a cellular substance, the method of preparation and uses thereof, in particular as an absorbent substance, and in particular for the manufacture of sponges and other products for household use. The cellular substance of the invention comprises a mixture of fibers of a hydrophilic polymer, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100021514 - Infection-resistant polyurethane foams, method for producing the same and use thereof in antiseptic wound dressings: The present invention describes microbicidal hydrophilic polyurethane foams endowed with polyhexamethylenebiguanide (PHMB) and/or its hydrochloride and also a superabsorbent, wound contact materials obtainable therefrom and processes for producing the therapeutically endowed polyurethane foams and the wound contact materials obtainable therefrom.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100021515 - Novel compositions of fungal inocula, method for the preparation thereof, and use thereof for improving the growth of cultures: This invention relates to novel compositions of fungal inocula, method for the preparation thereof, and use thereof for improving the growth of cultures.... Agent: Young & Thompson

20100021516 - Drug depots having one or more anchoring members: A drug depot implantable at or near a target tissue site beneath the skin of a patient is provided, the drug depot comprising a therapeutically effective amount of a drug and at least one surface adapted to receive one or more anchoring members so as to limit movement of the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100021517 - Non-woven fiber fabric: In order to provide a non-woven fiber fabric, in particular, in the form of a flat material or as part of a flat material which can be used as a biodegradable material in medicine, in particular, as an implant or carrier material for living cells (tissue engineering) but also a... Agent: Leydig Voit & Mayer, Ltd

20100021520 - Biomaterial implants: A biomaterial implant includes a mineralized collagen fibril scaffold. The collagen fibrils are formed from type I collagen monomers and display native-D band periodicity. The implant has load bearing capabilities and can be resorbed when implanted in a mammal's body.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100021519 - Compositions and methods for treating or preventing diseases of body passageways: The present invention provides compositions and methods for treating or preventing diseases associated with vascular and non-vascular body passageways, the method comprising the step of delivering to a body passageway a therapeutic agent delivered locally through a polymer matrix from an implanted stent or other structure.... Agent: Bell & Associates

20100021518 - Foam carrier for bone grafting: An improved osteogenic composition is provided. The composition comprises a foam that contains polymer beads having one or more growth factors such as bone morphogenic protein. Through use of this composition, bone, collagen and/or other tissue growth may be facilitated.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100021523 - Medical devices having inorganic barrier coatings: Medical devices having a barrier layer comprising an inorganic material. The medical device has a reservoir containing a therapeutic agent and the barrier layer is disposed over the reservoir. In one aspect, the barrier layer has one permeability to the therapeutic agent at one portion of the medical device and... Agent: Kenyon & Kenyon LLP

20100021524 - Pimethixene derivatives for promoting bone growth: The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.... Agent: Townsend And Townsend And Crew, LLP

20100021521 - Prosthesis for joint cartilage repair and method of manufacture: A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking... Agent: Raymond Sun

20100021522 - Sustained delivery of exenatide and other peptides: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.... Agent: Foley And Lardner LLP Suite 500

20100021525 - Method for producing sterol formulations: The invention relates to a method for producing coated sterol powders. According to said method, a) micronized sterol and/or stanol particles are provided in a mixer, b) the micronized sterol and/or stanol particles are wetted with a proteinaceous aqueous solution/dispersion, c) the wetted particles are mixed well and then dried,... Agent: Fox Rothschild LLP

20100021526 - Ph modulated films for delivery of actives: The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous... Agent: Hoffmann & Baron, LLP

20100021527 - Collagen-related peptides and uses thereof and hemostatic foam substrates: The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof. The present invention also relates to novel hemostatic foam substrates,... Agent: Philip S. Johnson Johnson & Johnson

20100021528 - Conformable structured therapeutic dressing: A conformable structured therapeutic dressing (120) has maximum available surface area (102) of a therapeutic agent (122) to stimulate therapeutic response in wounded tissue of a mammalian subject. In preferred embodiments, the therapeutic agent includes a procoagulant to quickly arrest bleeding and prevent life-threatening blood loss. The wound dressing exhibits... Agent: Stoel Rives LLP - Pdx

20100021530 - Enhanced trans-keratin drug delivery: The teachings provided herein are directed to a system and method for delivering an anti-infective agent through the nail of a subject having a nail infection. The system can comprise a drug delivery mechanism comprising an anti-infective agent and a heating element and a holding mechanism for releasably attaching the... Agent: Brian S. Boyer, Ph.d.

20100021529 - Step-down estrogen regimen for women receiving estrogen therapy: The present invention relates to methods for continuous treatment of diseases, conditions and/or symptoms associated with deficient endogenous levels of estrogen in a woman already receiving a therapeutically effective dose of an estrogen. More particularly, the present invention provides a safe and efficient step-down regimen for women already receiving estrogen... Agent: Millen, White, Zelano & Branigan, P.C.

20100021531 - Method for production of liposome preparation: Disclosed is a method which permits simple and easy production of a stable, high-quality liposome preparation suppressed in lipid degradation. This method can significantly shorten production time and can achieve a substantial cost cut-down in medium- to large-scale production, and can also attain the incorporation of a drug in uniform... Agent: Buchanan, Ingersoll & Rooney PC

20100021533 - Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance: A synergistic mixture (which may be utilized as a food or a drink or a supplement or a drug or a cosmetic or a hygienic product) that is formulated and is capable of improving a person's well being, lowering the risks of cardiovascular and/or Alzheimer's diseases and/or lowering blood sugar... Agent: Haynes And Boone, LLPIPSection

20100021532 - Personal care composition containing yeast/polyphenol ferment extract: Disclosed is a yeast/polyphenol ferment extract, and a personal care composition including the yeast/polyphenol ferment extract. Also disclosed is a method for preparing and using the yeast/polyphenol extract and the personal care composition.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100021534 - Injection-molded water soluble container: A rigid, water-soluble container is made of an injection molded poly(vinyl alcohol) and/or a cellulose ether, which container encases a fabric care, surface care or dishwashing composition; and a capsule container comprising at least two components made of one or more material(s) that can be molded and which are water... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100021535 - Light-stabilized soft capsule formulations: r

20100021536 - Enhanced-diffusion capsule: An ingestible capsule is provided for delivering medication to a subject. A capsule coating dissolves in a gastrointestinal tract of the subject. An inner core of the capsule has an outer surface associated therewith. The outer surface is disposed within the coating and expands when the coating dissolves. A medication... Agent: Sughrue Mion, PLLC

20100021537 - Stable digestive enzyme compositions: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric... Agent: Cooley Godward Kronish LLP

20100021538 - Pharmaceutical compositions containing heparin derivatives: An oral pharmaceutical composition for anticoagulation of blood includes a conjugate of an anticoagulation polysaccharide, such as heparin, covalently bonded to a hydrophobic agent wherein the conjugate is mixed with a solubilizer for inhibiting self-aggregation of the conjugate into nanoparticles. The composition can be coated, formed into tablets, or placed... Agent: Alan J. Howarth

20100021541 - Microparticulate form of a tetrahydropyridine derivative: The invention relates to a microparticulate form of 1-[2-(2-naphthyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride consisting of particles for which at least 55% of the population have a diameter below 50 micrometers, and to pharmaceutical compositions in which it is present.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100021539 - Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation: e

20100021540 - Tablets and preparation thereof: The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tabletting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant and the pre-tabletting... Agent: Paul D. Yasger Abbott Laboratories

20100021542 - Extended release oral dosage composition: A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent... Agent: Covington & Burling, LLP Attn: Patent Docketing

20100021543 - Peroral solid pain killer preparation: The invention relates to peroral solid analgesic formulations containing opioids and/or morphine analogues in an effect-retarding matrix.... Agent: Clements Bernard PLLC

20100021544 - Hydrogel and biomedical applications thereof: The invention relates to a method for preparing a cross-linked sterile and homogeneous hydrogel for injection, characterized in that it comprises the following steps: (a) preparing an aqueous solution containing a polymer derived from cellulose and at least one water-soluble polymer, the total polymer content ranging from 0.5 and 5... Agent: Pepper Hamilton LLP

20100021545 - Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof: Self-forming hybrid compositions consisting in admixed liquid and solid components enable the formation of bio-materials. The present invention proposes a) a thermo-sensitive self-forming liquid component, being water-based and containing at least a polycationic polymer such as chitosan, and an organic mono-phosphate source, which is a solution at a pH ranging... Agent: David S. Resnick

20100021546 - Controlled-release immunogenic formulations to modulate immune response: Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surface-erosion from in vivo hydrolysis of anhydride linkages at the surface of the microparticle, which results in controlled release... Agent: Schwegman, Lundberg & Woessner, P.A.

20100021547 - Pharmaceutical composition for piperidinoalkanol compounds: The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100021548 - Use of microparticles with adsorbed antigen to stimulate immune responses: The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen.... Agent: Novartis Vaccines And Diagnostics Inc.

20100021549 - Microparticle oral form useful for the modified release of nanoparticles: The present invention aims to propose novel microparticle oral forms for the modified release of active ingredient(s), in particular protein or peptide in nature. It also relates to the uses, in particular therapeutic or cosmetic, of these microparticle oral forms.... Agent: Patton Boggs LLP

20100021550 - Radiopaque biodegradable vascular embolic microspheres: A radiopaque biodegradable vascular embolic microsphere comprises of a biodegradable material and a radiopaque material which can be both delivered to the vascular system, in which, the biodegradable material incorporates the radiopaque material to form granule structure. The embolic microsphere, readily visible under X-ray, can be delivered or drift with... Agent: Myers Andras Sherman LLP

20100021554 - Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin: A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of... Agent: Elliot Furman

20100021553 - Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.... Agent: Panitch Schwarze Belisario & Nadel LLP

20100021552 - Polysaccharide nanofibers having antimicrobial properties: Polysaccharide nanofibers having anti-microbial properties, said nanofibers comprising an alginate and having silver nanoparticles dispersed throughout the nanofibers.... Agent: Convatec Inc.

20100021551 - Process for preparing nanoparticles of chitosan in water phase: l

20100021555 - Compositions containing high omega-3 and low saturated fatty acid levels: Food products and supplements comprising the essential unsaturated fatty acids EPA or DHA at high concentrations relative to other n-3 HUFAs and with relatively low levels of saturated fatty acids (myristic and palmitic acids) are provided. These compositions can be made in commercial quantities in a cost effective manner by... Agent: Duane Morris LLP - San Diego

20100021556 - Method for the production of an agent against an infectious disease: A method for producing an agent against an infectious disease, particularly HIV, Ebola, or similar. In the method, a pressurized, especially medical oxygen is swirled into a solution containing at least one plant component particularly in the form of an extract.... Agent: Bachman & Lapointe, P.C.

20100021558 - Dilute aqueous peracid solutions and stabilization method: A method for stabilizing a dilute peracetic acid solution containing less than about 5 wt % peracetic acid by controlling the concentration of hydrogen peroxide and the mole ratio of hydrogen peroxide to acetic acid and by introducing a stabilizer to provide sequestering activity. The method is particularly useful for... Agent: Patent Administrator Fmc Corporation

20100021557 - Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds... Agent: Ecolab Inc.

20100021560 - Products of bamboo charcoal supporting silver: A silver-supporting bamboo charcoal (BC/Ag) comprising silver in different weight ratio of 26% (BC/Ag-1), 29% (BC/Ag-2), 34% (BC/Ag-3), 48% (BC/Ag-4), 57% (BC/Ag-5), or 75% (BC/Ag-6). The BC powders (particle size<10 μm, Taiwan Paiho) are activated with surfactant sodium alginate under stirred for 1 h. The as-prepared BC powders (2 g)... Agent: Nikolai & Mersereau, P.A.

20100021559 - Zeolite supported metallic nanodots: A metal nanodot material is formed by ion-exchange with chabazite or a chabazite-like structure, followed by activation to form metallic nanodots. The nanodot may be formed from silver, nickel, copper, gold or a platinum group metal.... Agent: Edward Yoo C/o Bennett Jones

20100021562 - Self preserved aqueous pharmaceutical compositions: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being ‘self-preserved’. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the... Agent: Alcon

20100021561 - Self-preserved aqueous pharmaceutical compositions: The use of borate/amino alcohol/zinc systems to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being “self-preserved”. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for... Agent: Alcon

20100021563 - Compositions comprising coconut oil and methods of use thereof: The present disclosure relates to natural and/or homeopathic compositions comprising coconut oil in a form suitable for topical administration to a subject and having one or more health-promoting property, including those for treatment and/or prevention of disease, and methods for use thereof. The present disclosure further relates to natural and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100021564 - Om vitamin formula: I have BS in Science and MS in Mathematics from India. I have MS in Engineering from UT Austin Tex. Currently, I am working as an Engineer for Dept. of Defense. I sought medical help once I started having multitude of ill-health symptoms. I was prescribed pain killer, sleeping tablets,... Agent: Renuka Maewal

20100021565 - Pearlescent pigments: The present invention relates to pearlescent pigments based on flake-form substrates which have at least one FeOOH layer and at least one TiO2 layer or at least one TiO2/SiO2/TiO2 layer package, and to the use thereof, inter alia, in paints, coatings, printing inks, powder coatings, plastics and in particular in... Agent: Millen, White, Zelano & Branigan, P.C.

20100021566 - Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a... Agent: Barnes & Thornburg LLP

20100021568 - Anti-obesity product and its method of preparation: The present invention relates to compositions comprising one or more anthraquinones for use in the treatment of obesity and related metabolic and liver disease. More particularly it relates to a plant extract fraction rich in anthraquinones including both anthraquinone glycosides and anthraquinone aglycones obtainable from a member of the Leguminosae... Agent: Dickinson Wright PLLC

20100021567 - Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets: This patent concerns the discovery of the effectiveness of an alcoholic total extract of the aerial parts of the plant Anisotes trisulcus (Forssk.) Vahl family Acanthaceae and its active constituent peganine as a new means for suppression of tobacco intake and as a suppression to appetite (as anororexiants). The treatment... Agent: Al-rehaily Adnan Jathlan Associate Professor

20100021569 - Use of extracts from amths plants in lowering blood glucose: The present invention discloses the use of extracts from the plants of the genus Amaranthus, such as the extracts from Amaranthus mangostanus L. and Amaranthus tricolor L., in lowering the blood glucose level. The present invention further provides anti-diabetes compositions or blood glucose-regulating dietary supplements, which contain the Amaranthus plant... Agent: G. Link Co., Ltd.

20100021570 - Smoking cessation treatment by reducing nicotine cravings, apetite suppression, and altering the perceived taste of tobacco smoke: A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur... Agent: John C. Smith, Esq.

20100021571 - Compositions and methods for treating acne: This invention provides anti-acne kits that are useful for treating acne, especially severe cases of acne. The anti-acne kits include a vasoconstrictor and an anti-acne agent, and optionally one or more of a a skin lightening therapeutic, a sealing layer, a skin cleanser, an astringent, a skin penetration enhancer, a... Agent: King & Spalding

20100021572 - Nutritional drink: A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance... Agent: James David Johnson, P.A.

20100021573 - Compositions and methods for the prevention of cardiovascular disease: The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ10,... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100021574 - Pharmaceutical composition and procedure to treat and prevent prostatic hyperplasia and prostatitis from the royal palm (roystonea regia) fruits: A method for obtaining a pharmaceutical composition from Roystonea regia whole fruit including drying, grinding, and sieving the Roystonea regia whole fruit, and separating an extract through a solid/liquid extraction in organic solvents with the organic solvents are selected from hydrocarbons of 5 to 8 carbon atoms, alcohols of 1... Agent: Lackenbach Siegel, LLP

20100021575 - Hypolipidemic composition and its use: The present invention provides a hypolipidemic composition comprising peony extract and Codonopsis extract, or comprising water coextract of peony and Codonopsis, the weight ratio of the peony extract to Codonopsis extract in the composition is between 0.5 and 19:1. The advantages of the hypolipidemic composition are: substantially decreasing triglyceride and... Agent: Yuan Qing Jiang

20100021576 - Bacillus amyloliquefaciens k317 for suppressing the growth of antibiotics-resistant pathogenic microorganism or enteropathogenic microorganism: The present invention relates to a Bacillus amyloliquefaciens K317 strain suppressing the growth of antibiotics-resistant pathogenic microorganisms or enteropathogenic microorganisms, more precisely a Bacillus amyloliquefaciens K317 strain, a culture supernatant thereof and an antibacterial metabolite separated from the same. The Bacillus amyloliquefaciens K317 strain, the culture supernatant thereof and the... Agent: Greenlee Winner And Sullivan P C